ERBB2 and breast carcinoma: However, in HER2-enriched subtype stage IV breast cancer patients, after adjusted for sociodemographic factors, clinical-pathological characteristics and therapeutic methods, there was no significant difference in prognosis between younger than or equal to 40 years and of age 51 to 60 years (HR, 0.77; 95% CI, 0.58-1.04).